RT Journal Article
SR Electronic
T1 Identification and treatment of T2-low asthma in the era of biologics
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 00309-2020
DO 10.1183/23120541.00309-2020
VO 7
IS 2
A1 Kyriakopoulos, Chris
A1 Gogali, Athena
A1 Bartziokas, Konstantinos
A1 Kostikas, Konstantinos
YR 2021
UL http://openres.ersjournals.com/content/7/2/00309-2020.abstract
AB Currently, and based on the development of relevant biologic therapies, T2-high is the most well-defined endotype of asthma. Although much progress has been made in elucidating T2-high inflammation pathways, no specific clinically applicable biomarkers for T2-low asthma have been identified. The therapeutic approach of T2-low asthma is a problem urgently needing resolution, firstly because these patients have poor response to steroids, and secondly because they are not candidates for the newer targeted biologic agents. Thus, there is an unmet need for the identification of biomarkers that can help the diagnosis and endotyping of T2-low asthma.Ongoing investigation is focusing on neutrophilic airway inflammation mediators as therapeutic targets, including interleukin (IL)-8, IL-17, IL-1, IL-6, IL-23 and tumour necrosis factor-α; molecules that target restoration of corticosteroid sensitivity, mainly mitogen-activated protein kinase inhibitors, tyrosine kinase inhibitors and phosphatidylinositol 3-kinase inhibitors; phosphodiesterase (PDE)3 inhibitors that act as bronchodilators and PDE4 inhibitors that have an anti-inflammatory effect; and airway smooth muscle mass attenuation therapies, mainly for patients with paucigranulocytic inflammation.This article aims to review the evidence for noneosinophilic inflammation being a target for therapy in asthma; discuss current and potential future therapeutic approaches, such as novel molecules and biologic agents; and assess clinical trials of licensed drugs in the treatment of T2-low asthma.Th2-low endotype of asthma occurs in 50% of asthma patients. Novel targeted treatment with biologic agents is not currently approved. Nevertheless, other therapeutic options exist. Licensed drugs, novel molecules and biologics agents are under development. https://bit.ly/3bW7G0Q